OBJECTIVE: Alzheimer disease (AD) and frontotemporal lobar degeneration (FTLD) may have overlapping clinical presentations despite distinct underlying neuropathologies, thus making in vivo diagnosis challenging. In this study, we evaluate the utility of MRI as a noninvasive screening procedure for the differential diagnosis of AD and FTLD. METHODS: We recruited 185 patients with a clinically diagnosed neurodegenerative disease consistent with AD or FTLD who had a lumbar puncture and a volumetric MRI. A subset of 32 patients had genetic or autopsy-confirmed AD or FTLD. We used singular value decomposition to decompose MRI volumes and linear regression and cross-validation to predict CSF total tau (tt) and β-amyloid (Aβ(1-42)) ratio (tt/Aβ) in patients with AD and patients with FTLD. We then evaluated accuracy of MRI-based predicted tt/Aβ using 4 converging sources including neuroanatomic visualization and categorization of a subset of patients with genetic or autopsy-confirmed AD or FTLD. RESULTS: Regression analyses showed that MRI-predicted tt/Aβ is highly related to actual CSF tt/Aβ. In each group, both predicted and actual CSF tt/Aβ have extensively overlapping neuroanatomic correlates: low tt/Aβ consistent with FTLD is related to ventromedial prefrontal regions while high tt/Aβ consistent with AD is related to posterior cortical regions. MRI-predicted tt/Aβ is 75% accurate at identifying underlying diagnosis in patients with known pathology and in clinically diagnosed patients with known CSF tt/Aβ levels. CONCLUSION: MRI may serve as a noninvasive procedure that can screen for AD and FTLD pathology as a surrogate for CSF biomarkers.
OBJECTIVE:Alzheimer disease (AD) and frontotemporal lobar degeneration (FTLD) may have overlapping clinical presentations despite distinct underlying neuropathologies, thus making in vivo diagnosis challenging. In this study, we evaluate the utility of MRI as a noninvasive screening procedure for the differential diagnosis of AD and FTLD. METHODS: We recruited 185 patients with a clinically diagnosed neurodegenerative disease consistent with AD or FTLD who had a lumbar puncture and a volumetric MRI. A subset of 32 patients had genetic or autopsy-confirmed AD or FTLD. We used singular value decomposition to decompose MRI volumes and linear regression and cross-validation to predict CSF total tau (tt) and β-amyloid (Aβ(1-42)) ratio (tt/Aβ) in patients with AD and patients with FTLD. We then evaluated accuracy of MRI-based predicted tt/Aβ using 4 converging sources including neuroanatomic visualization and categorization of a subset of patients with genetic or autopsy-confirmed AD or FTLD. RESULTS: Regression analyses showed that MRI-predicted tt/Aβ is highly related to actual CSF tt/Aβ. In each group, both predicted and actual CSF tt/Aβ have extensively overlapping neuroanatomic correlates: low tt/Aβ consistent with FTLD is related to ventromedial prefrontal regions while high tt/Aβ consistent with AD is related to posterior cortical regions. MRI-predicted tt/Aβ is 75% accurate at identifying underlying diagnosis in patients with known pathology and in clinically diagnosed patients with known CSF tt/Aβ levels. CONCLUSION: MRI may serve as a noninvasive procedure that can screen for AD and FTLD pathology as a surrogate for CSF biomarkers.
Authors: Anne M Fagan; Denise Head; Aarti R Shah; Daniel Marcus; Mark Mintun; John C Morris; David M Holtzman Journal: Ann Neurol Date: 2009-02 Impact factor: 10.422
Authors: Leslie M Shaw; Hugo Vanderstichele; Malgorzata Knapik-Czajka; Christopher M Clark; Paul S Aisen; Ronald C Petersen; Kaj Blennow; Holly Soares; Adam Simon; Piotr Lewczuk; Robert Dean; Eric Siemers; William Potter; Virginia M-Y Lee; John Q Trojanowski Journal: Ann Neurol Date: 2009-04 Impact factor: 10.422
Authors: H Bian; J C Van Swieten; S Leight; L Massimo; E Wood; M Forman; P Moore; I de Koning; C M Clark; S Rosso; J Trojanowski; V M-Y Lee; M Grossman Journal: Neurology Date: 2008-05-06 Impact factor: 9.910
Authors: G D Rabinovici; W W Seeley; E J Kim; M L Gorno-Tempini; K Rascovsky; T A Pagliaro; S C Allison; C Halabi; J H Kramer; J K Johnson; M W Weiner; M S Forman; J Q Trojanowski; S J Dearmond; B L Miller; H J Rosen Journal: Am J Alzheimers Dis Other Demen Date: 2007 Dec-2008 Jan Impact factor: 2.035
Authors: K B Walhovd; A M Fjell; J Brewer; L K McEvoy; C Fennema-Notestine; D J Hagler; R G Jennings; D Karow; A M Dale Journal: AJNR Am J Neuroradiol Date: 2010-01-14 Impact factor: 3.825
Authors: Kurt R Brunden; Carlo Ballatore; Alex Crowe; Amos B Smith; Virginia M-Y Lee; John Q Trojanowski Journal: Exp Neurol Date: 2009-09-08 Impact factor: 5.330
Authors: Sergi G Costafreda; Ivo D Dinov; Zhuowen Tu; Yonggang Shi; Cheng-Yi Liu; Iwona Kloszewska; Patrizia Mecocci; Hilkka Soininen; Magda Tsolaki; Bruno Vellas; Lars-Olof Wahlund; Christian Spenger; Arthur W Toga; Simon Lovestone; Andrew Simmons Journal: Neuroimage Date: 2011-01-25 Impact factor: 6.556
Authors: Yu Zhang; Norbert Schuff; Christopher Ching; Duygu Tosun; Wang Zhan; Marzieh Nezamzadeh; Howard J Rosen; Joel H Kramer; Maria Luisa Gorno-Tempini; Bruce L Miller; Michael W Weiner Journal: Int J Alzheimers Dis Date: 2011-06-27
Authors: Jennifer L Whitwell; Stephen D Weigand; Bradley F Boeve; Matthew L Senjem; Jeffrey L Gunter; Mariely DeJesus-Hernandez; Nicola J Rutherford; Matthew Baker; David S Knopman; Zbigniew K Wszolek; Joseph E Parisi; Dennis W Dickson; Ronald C Petersen; Rosa Rademakers; Clifford R Jack; Keith A Josephs Journal: Brain Date: 2012-03 Impact factor: 13.501
Authors: Corey T McMillan; Brian B Avants; Philip Cook; Lyle Ungar; John Q Trojanowski; Murray Grossman Journal: Hum Brain Mapp Date: 2014-03-31 Impact factor: 5.038
Authors: Corey T McMillan; David J Irwin; Brian B Avants; John Powers; Philip A Cook; Jon B Toledo; Elisabeth McCarty Wood; Vivianna M Van Deerlin; Virginia M-Y Lee; John Q Trojanowski; Murray Grossman Journal: J Neurol Neurosurg Psychiatry Date: 2013-03-09 Impact factor: 10.154
Authors: David J Irwin; Nigel J Cairns; Murray Grossman; Corey T McMillan; Edward B Lee; Vivianna M Van Deerlin; Virginia M-Y Lee; John Q Trojanowski Journal: Acta Neuropathol Date: 2014-12-31 Impact factor: 17.088
Authors: Jon B Toledo; Vivianna M Van Deerlin; Edward B Lee; EunRan Suh; Young Baek; John L Robinson; Sharon X Xie; Jennifer McBride; Elisabeth M Wood; Theresa Schuck; David J Irwin; Rachel G Gross; Howard Hurtig; Leo McCluskey; Lauren Elman; Jason Karlawish; Gerard Schellenberg; Alice Chen-Plotkin; David Wolk; Murray Grossman; Steven E Arnold; Leslie M Shaw; Virginia M-Y Lee; John Q Trojanowski Journal: Alzheimers Dement Date: 2013-08-24 Impact factor: 21.566
Authors: Xiao Da; Jon B Toledo; Jarcy Zee; David A Wolk; Sharon X Xie; Yangming Ou; Amanda Shacklett; Paraskevi Parmpi; Leslie Shaw; John Q Trojanowski; Christos Davatzikos Journal: Neuroimage Clin Date: 2013-11-28 Impact factor: 4.881
Authors: Lucia A A Giannini; David J Irwin; Corey T McMillan; Sharon Ash; Katya Rascovsky; David A Wolk; Vivianna M Van Deerlin; Edward B Lee; John Q Trojanowski; Murray Grossman Journal: Neurology Date: 2017-05-17 Impact factor: 9.910